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Background/Aims
In patients with non-cardiac chest pain (NCCP), gastroesophageal reflux disease (GERD) is the commonest cause and ambula-
tory pH is of great value in identifying these patients. However, parameters in the context of predicting therapeutic response 
are still unknown. By extending the monitoring period, we could better evaluate the best evidence for GERD association. Our 
aims were (1) to compare the outcomes of 48-hour pH monitoring to 24-hour and (2) to determine whether objective param-
eters could predict the treatment success in patients with NCCP using Bravo pH system. 
Methods
Pathological esophageal acid reflux (PEAR) and positive symptom index (SI) were calculated after 24-hour and compared to the 
48-hour study. Evidence suggestive of GERD diagnosis was considered if PEAR and/or SI (＋) were present on each different day. After 
pH study, all patients received proton pump inhibitor twice a day for 4 weeks. Treatment success was determined at the end of therapy.
Results
Thirty-two patients with NCCP participated. GERD was identified in 20 (62.5%) patients; 17 (53.1%) had PEAR, 3 (9.4%) SI 
(＋) and 7 (22%) both. Twelve (41%) patients exhibited PEAR values on day 1, while 17 after 2 days; a 12.1 % gain. SI (＋) 
was found in 6 patients (18.8%) on day 1 and in 4 more on day 2, a gain of 12.5%. Significantly higher proportion of pa-
tients with GERD indicators showed improvement compared to those without (90% vs 16.7%, P ＜  0.005).
Conclusions
In patients with NCCP, 48-hour pH measurement identified GERD as the cause of NCCP with an increased yield by almost 12% 
compared to 12 hours. Objective GERD parameters could predict response to antireflux therapy.
(J Neurogastroenterol Motil 2012;18:169-173)
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Introduction
Non-cardiac chest pain (NCCP) is a heterogeneous disorder 
defined as ‘angina-like’ chest pain that is not due to ischemic 
heart disease or other cardiac pathology.
1 Of those patients who 
presented to an emergency room with chest pain, a cardiac etiol-
ogy was ultimately found in only 11% to 39%.
2,3 The esophagus 
is the most common source of NCCP, with gastroesophageal re-
flux disease (GERD) constituting up to 60% of the cases.
1,4 
Typical reflux symptoms were found to be significantly and in-
dependently associated with the presence of NCCP. The preva-
lence of NCCP among patients with frequent and no reflux 
symptoms was 37.6% and 12.2%, respectively.
5
The diagnostic tests available include gastroscopy, esoph-
ageal manometry, ambulatory 24-hour esophageal pH monitor-
ing and an empirical trial with high-dose proton pump inhibitor 
(PPI).
4-7 Upper endoscopy has been suggested to have a very 
limited value in NCCP patients, because of the low prevalence of 
esophageal mucosal findings. Ambulatory pH monitoring is par-
ticularly helpful in those patients who had normal endoscopy and 
failed to respond to a therapeutic trial with PPI.
1 Abnormal pH 
testing was documented in 40%-50% of the patients.
8,9 In pa-
tients with NCCP who had a normal pH test, calculation of 
symptom association parameters could increase the sensitivity of 
the test.
10
With the evolution of new techniques, such as wireless pH 
monitoring, we have gained the advantage of extending the mon-
itoring period upto 48 hours. Thus, the approach appeared to in-
crease the yield for detecting abnormal esophageal acid exposure 
and the likelihood of establishing a relationship between reflux 
events and symptoms.
11-14 However, the value of esophageal pa-
rameters in implicating GERD as the etiology of NCCP could 
be more helpful in predicting the response to antireflux therapy. 
As far as we know there are no data regarding the evaluation on 
the effectiveness of NCCP treatment guided by objective param-
eters determined with wireless ambulatory pH testing.
The aims of our study were (1) to evaluate the additional 
yield of 48-hour pH monitoring compared to 24-hour pH mon-
itoring using a wireless ambulatory pH system in patients with 
NCCP and (2) to determine whether objective esophageal pa-
rameters could predict treatment success in these patients. 
Materials and Methods
Study Population
We included patients who had at least 3 episodes of chest 
pain per week in the previous 3 months. Patients had undergone 
a comprehensive diagnostic evaluation by cardiologists in order to 
exclude a cardiac source for their chest pain. Patients recruited 
for the study had either normal coronary angiogram or lack of is-
chemic heart disease on exercise treadmill or stress thallium 
testing. Informed written consent was obtained from all partici-
pated patients. Patients were excluded if they were using aspirin 
or NSAIDs, had a history of upper gastrointestinal surgery, gas-
tric or duodenal ulcer, connective tissue disease, and severe liver, 
lung, renal or haematological disease. All patients had a normal 
esophageal manometry in order to exclude the presence of any 
esophageal motility disorder.
Ambulatory pH Monitoring
Ambulatory esophageal pH monitoring was performed using 
the wireless pH capsule system (BRAVO
TM pH System; 
Medtronic Inc., Shoreview, MN, USA). The system allows 
monitoring for 2 consecutive days. Before each study, the pH 
probe was calibrated in buffer solutions of pH 7 and 1. The probe 
was deployed at 6 cm proximal to the squamocolumnar junction, 
defined by previous upper endoscopy, after transoral introduction 
using standard placement technique.
11,12
Study Protocol
All patients filled out a detailed questionnaire about symp-
toms and underwent an upper gastrointestinal endoscopy. 
Ambulatory 24-hour esophageal pH monitoring was performed 
on one of the next 7 days. Treatment with PPI was discontinued 
for at least 15 days; all other drugs potentially affecting gastro-
intestinal motility and gastrointestinal secretion were disconti-
nued at least 1 week prior to the study.
Data collection device was worn in a belt on the patient’s 
waist. Patients were instructed to resume daily activity and diet. 
They also recorded the time of meal consumption, indicated the 
occurrence of symptoms and posture changes on a diary card. 
Data analysis was performed using standard commercially avail-
able computer software program (Polygram
TM NET; Medtro-
nic, Minneapolis, MN, USA).Bravo 48-hour pH-metry in NCCP Patients
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Figure. Prevalence of indicators of GERD on each day of 48-hour 
wireless ambulatory pH monitoring. GERD, gastroesophageal reflux 
disease; PEAR, pathological esophageal acid reflux; SI, symptom index.
Data Analysis
For the analysis, the periods of meal consumption were 
marked and excluded. Percentage of time with esophageal pH < 
4 was calculated and pathological esophageal acid reflux (PEAR) 
was present when esophageal pH was below 4 for > 5.8% on day 
1 or below 4.5% on day 2.
15 The symptom index (SI) was calcu-
lated for each patient in relation to acid reflux episodes. Symptom 
was considered to be associated with reflux if it was preceded 
within 2 minutes by a reflux episode.
16 A positive SI was defined 
if > 50% of the symptoms were associated with pathological 
reflux.
17 If PEAR and/or positive SI were present on either day 1 
or day 2, it was considered as an evidence suggestive of GERD 
diagnosis..
Treatment Schedule
All patients (regardless of whether having parameters im-
plicating GERD as the etiology of NCCP or otherwise) under-
went a therapeutic trial of PPIs twice daily for 4 weeks. The im-
provement of symptom was assessed by face-to-face interview at 
the end of antireflux therapy using a 4-point Likert scale (0 = no 
improvement, 1 = mild improvement, 2 = moderate improve-
ment and 3 = marked improvement). Treatment success was de-
fined as the presence of moderate or marked improvement in 
NCCP symptom.
Statistical Methods
Values were expressed as mean ± SD. Statistical analysis was 
performed by Student’s t test or Chi-square testing wherever 
appropriate. All P-values < 0.05 were considered to be significant.
Results
Patient Characteristics
Thirty-two patients (18 men, mean age: 45.3 ± 12.5 years) 
participated in the 2-day ambulatory pH monitoring. The wire-
less capsule was successful in all patients who underwent the 
study. None of the patients required a premature termination of 
the study or the endoscopic removal of the wireless capsule. Most 
patients tolerated the wireless pH capsule well without any 
discomfort. Four patients (12.5%)  reported symptoms possibly 
related to capsule placement which included throat pain,
3 back 
pain
2 and globus sensation.
1
Pathological Esophageal Acid Reflux
A total of 17 (53.1%) patients had PEAR. Twelve (41%) pa-
tients exhibited abnormal values on day 1 and 17 (53.1%) pa-
tients on either day of the 2-day study. The overall detection of 
abnormal esophageal acid exposure was increased by 12.1% with 
the addition of day 2 recording.
Symptoms 
Chest pain episodes were reported by 25 (78%) patients dur-
ing the study period. Extending the recording time increased the 
number of patients reporting symptoms from 21 (66%) on day 1 
to 25 by the end of the study (12% increase). Moreover, the num-
ber of symptoms available for analysis was almost doubled from 
24 to 48 hours (9.2 ± 2.1 vs 18.3 ± 3.9, P < 0.001). 
Symptom-reflux Association
In 10 (31.3%) patients a positive SI was found; 6 patients 
(18.8%) had positive SI on day 1, while 4 more on day 2. A gain 
of 12.5% of the patients was observed at the end of the 48-hour 
recording. Considering the outcomes of both PEAR and positive 
SI, a positive SI in conjunction with PEAR was found in 7 (22%) 
patients. Addition of SI as an indicator suggesting GERD diag-
nosis resulted in gaining a total of 3 (9.4%) more patients. Figure 
showed the prevalence of indicators of GERD on each day of pH 
monitoring.Georgios Karamanolis, et al
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Treatment Response (Objective Pathological 
Esophageal Parameters Versus Normal Esopha-
geal Parameters)
Of patients with NCCP who had abnormal objective GERD 
evidence, 18 (90%) experienced moderate or marked symptom 
improvement. This contrasts significantly with the group of pa-
tients without presence of GERD indicators, where only 2 
(16.7%) patients showed moderate improvement (P < 0.005). 
Only 2 patients with PEAR as the parameter suggesting 
GERD did not show improvement at the end of treatment. 
Discussion
Our results showed that over 60% of study population had 
evidence of GERD indicators on the ambulatory pH monitoring. 
By using a wireless pH monitoring which extended the recording 
time to 48 hours we found an increased yield in detection of 
GERD as the cause of chest pain in these patients. We also im-
proved the detection of abnormal degrees of esophageal acid re-
flux by extending the pH recording beyond 24 hours. By the end 
of the 48 hours study, almost 12 % of patients had evidence of 
GERD (either PEAR or positive SI) only on day 2. Thus, before 
the advent of 48 hours wireless pH testing this proportion of pa-
tients would have been identified as negative for GERD and rep-
resents the increased diagnostic yield of this technique compared 
with 24 hours pH testing. Moreover, we showed that the pres-
ence of objective GERD parameters, such as PEAR and/or pos-
itive SI could predict a high symptomatic response to therapy 
with PPIs in patients with NCCP.   
Because GERD is by far the most common etiology for 
NCCP, identification of a GERD-mediated etiology for NCCP 
is an important process in the evaluation of these patients. 
Association between chest pain episodes and acid reflux events is 
considered to reduce repeatitive testing for alternate etiologies, 
ameliorate patient concerns, and decrease functional disability.
2 
PEAR was found in 53% of our patients, a figure that was higher 
than those observed in studies using conventional catheter-based 
devices.
18,19 This increased rate represents the additional yield 
gained by extending the recording period from 1 to 2 days. This 
increased diagnostic yield was consistent with previously pub-
lished studies.
14,20 It showed an almost 10% gain of pathological 
acid reflux recording with 48-hour monitoring compared to 
24-hour monitoring using a wireless pH device. The advantages 
of extending the duration of pH monitoring were also evident in 
patients with typical or atypical GERD symptoms.
11-13
PEAR suggests presence of GERD, but correlation between 
reflux events and chest pain episodes is required to attribute 
GERD as the etiology of chest pain.
21 Symptom index is the most 
commonly used test for assessing reflux-symptom association. 
We found that almost 30% of patients had a positive SI during 
the study period. This rate was consistent with the previous study 
using wireless pH device but was higher compared to the results 
of a study using catheter-based device.
14,22 Extending the record-
ing time almost doubled the number of chest pain episodes re-
ported and also increased the number of patients reporting symp-
toms by 12%. Thus, lengthening pH monitoring time improved 
our ability to establish GERD as the cause of chest pain in our 
study population. A gain of 12.5% of the patients with a positive 
SI as GERD indicator was observed at the end of the 48-hour 
recording. Although the majority of patients with a positive SI 
had also pathological acid reflux, addition of SI resulted in an in-
crease of detection of patients with evidence of GERD by 10%. 
The combination of a positive SI and pathological acid reflux on 
wireless pH monitoring identified 62.5% of patients with evi-
dence linking GERD to NCCP. 
According to most recently published review regarding 
NCCP, after exclusion of cardiac origin pain, twice-daily PPI 
should be tried before other invasive tests including ambulatory 
pH testing.
23 H o w e v e r ,  i n  p a t i e n t s  w i t h  u n s e l e c t e d  G E R D  
symptoms, the specificity of a PPI trial for a GER diagnosis has 
been reported as low as 54%.
24 It is also known that some patients 
with NCCP failed to response to short term treatments with 
PPIs.
25 For these reasons, ambulatory pH testing is of great val-
ue in determining GERD as the cause of NCCP. Identification 
of abnormal objective pH parameters, including PEAR and pos-
itive SI emphasize also the value of pH monitoring in predicting 
therapeutic success in patients with NCCP. Indeed, our study 
showed that marked improvement of symptoms was observed in 
90% of patients with abnormal objective GERD indicators. In 
contrast, only 17% of patients without relevant GERD parame-
ters showed improvement after PPI treatment. Our result is in 
agreement with a recent study showing that response to antireflux 
therapy was best predicted when GERD parameters were abnor-
mal and poorest when parameters were normal.
10
In conclusion, our study showed that combination of a pos-
itive SI and pathological acid reflux could identify GERD as the 
etiology of chest pain in 62.5% of patients with NCCP. By ex-
tending the period of pH monitoring to 2 days using a wireless 
pH device we observed an increased yield in detecting evidence Bravo 48-hour pH-metry in NCCP Patients
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of GERD in patients with NCCP by almost 12%. Presence of 
objective abnormal GERD parameters could better predict re-
sponse to PPI therapy compared to presence of normal GERD 
indicators.
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